Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/prevention-of-postmenopausal-osteoporosis-with-pharmacological-therapy-GaxCG8hqKO
References (112)
-
E. Seeman, P. Delmas (2001)
Reconstructing the skeleton with intermittent parathyroid hormoneTrends in Endocrinology & Metabolism, 12
-
S. Gerlach (1981)
Diagnosis and Therapy -
J. Body, A. Lortholary, G. Romieu, A. Vigneron, J. Ford (1999)
A Dose‐Finding Study of Zoledronate in Hypercalcemic Cancer PatientsJournal of Bone and Mineral Research, 14
-
2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis
Endocr Pract, 7
-
S. Harris, N. Watts, R. Jackson, H. Genant, R. Wasnich, P. Ross, P. Miller, A. Licata, C. Chestnut (1993)
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.The American journal of medicine, 95 6
-
P. Daele, M. Seibel, H. Burger, A. Hofman, D. Grobbee, J. Leeuwen, J. Birkenhager, H. Pols (1996)
Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam studyBMJ, 312
-
Jacques Brown, D. Kendler, M. McClung, R. Emkey, J. Adachi, M. Bolognese, Zhengqing Li, A. Balske, R. Lindsay (2002)
The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal OsteoporosisCalcified Tissue International, 71
-
D. McDonnell (1999)
The Molecular Pharmacology of SERMsTrends in Endocrinology & Metabolism, 10
-
A. Looker, H. Wahner, W. Dunn, M. Calvo, T. Harris, S. Heyse, C. Johnston, R. Lindsay (1998)
Updated Data on Proximal Femur Bone Mineral Levels of US AdultsOsteoporosis International, 8
-
S. Hodgson, Mace, N. Watts, J. Bilezikian, B. Clarke, T. Gray, D. Harris, C. Johnston, M. Kleerekoper, R. Lindsay, M. Luckey, M. McClung, H. Nankin, S. Petak, R. Recker, R. Anderson, D. Bergman, Z. Bloomgarden, R. Dickey, P. Palumbo, A. Peters, Herbert Rettinger, H. Rodbard, H. Rubenstein (2001)
American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 7 4
-
Herbert Fleisch (1998)
Bisphosphonates: mechanisms of actionExpert Opinion on Therapeutic Patents, 11
-
S. Nielsen, O. Bärenholdt, F. Hermansen, N. Munk-Jensen (1994)
Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatmentBJOG: An International Journal of Obstetrics & Gynaecology, 101
-
D. Black, S. Cummings, L. Melton (1992)
Appendicular bone mineral and a woman's lifetime risk of hip fractureJournal of Bone and Mineral Research, 7
-
D. Black, S. Cummings, D. Karpf, J. Cauley, D. Thompson, M. Nevitt, D. Bauer, H. Genant, W. Haskell, R. Marcus, S. Ott, J. Torner, S. Quandt, T. Reiss, K. Ensrud (1996)
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 348
-
M. Hochberg, P. Ross, D. Black, S. Cummings, H. Genant, M. Nevitt, E. Barrett-Connor, T. Musliner, D. Thompson (1999)
Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.Arthritis and rheumatism, 42 6
-
P. Meunier, E. Confavreux, I. Tupinon, C. Hardouin, P. Delmas, R. Balena (1997)
Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)The Journal of clinical endocrinology and metabolism, 82 9
-
Pernille Ravn, S. Weiss, J. Rodriguez-Portales, M. McClung, R. Wasnich, N. Gilchrist, P. Sambrook, I. Fogelman, D. Krupa, A. Yates, A. Daifotis, G. Fuleihan (2000)
Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.The Journal of clinical endocrinology and metabolism, 85 4
-
(2001)
Osteoporosis . Clinical Guidelines for Prevention and Treatment . Update on Pharmacological Interventions and an Algorithm for Management -
(1999)
Long-term prevention of postmenopausal bone loss with alendronate. Effects of continuous treatment and after withdrawal. 81st Annual Meeting of the -
P. Ravn, M. Bidstrup, R. Wasnich, J. Davis, M. McClung, A. Balske, C. Coupland, O. Sahota, A. Kaur, M. Daley, G. Cizza (1999)
Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.Annals of internal medicine, 131 12
-
Bonar Bonar, Tinetti Tinetti, Speechley Speechley, Conney Conney (1990)
Factors associated with short‐ versus long‐term skilled nursing facility placement among community‐living hip fracture patientsJ Am Geriatr Soc, 38
-
(2000)
A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): results of a 3-year trial -
J. Reginster, H. Minne, O. Sørensen, M. Hooper, C. Roux, M. Brandi, B. Lund, D. Ethgen, S. Pack, I. Roumagnac, R. Eastell, O. Group (2000)
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 11
-
S. Harris, N. Watts, H. Genant, C. McKeever, T. Hangartner, Michael Keller, C. Chesnut, Jacques Brown, E. Eriksen, M. Hoseyni, D. Axelrod, P. Miller (1999)
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.JAMA, 282 14
-
C. Rosen (2004)
Treatment of Postmenopausal Osteoporosis: An Evidence-Based ApproachReviews in Endocrine and Metabolic Disorders, 2
-
C. Chesnut, A. Skag, C. Christiansen, R. Recker, J. Stakkestad, A. Høiseth, D. Felsenberg, H. Huss, J. Gilbride, R. Schimmer, P. Delmas (2004)
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 19
-
M. McClung, B. Clemmesen, A. Daifotis, N. Gilchrist, J. Eisman, R. Weinstein, G. Fuleihan, C. Reda, A. Yates, P. Ravn (1998)
Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled TrialAnnals of Internal Medicine, 128
-
M. McClung, R. Wasnich, R. Recker, J. Cauley, C. Chesnut, K. Ensrud, A. Burdeska, Tracy Mills (2003)
Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without OsteoporosisJournal of Bone and Mineral Research, 19
-
J. Kanis, P. Delmas, P. Burckhardt, C. Cooper, D. Torgerson (1997)
Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 7 4
-
Consensus development conference: prophylaxis and treatment of osteoporosis
Am J Med, 90
-
(2002)
Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis -
Graeme Jones, Tuan Nguyen, P. Sambrook, P. Kelly, C. Gilbert, J. Eisman (1994)
Symptomatic fracture incidence in elderly men and women: The Dubbo osteoporosis epidemiology study (DOES)Osteoporosis International, 4
-
S. Goldstein, N. Nanavati (2002)
Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study.American journal of obstetrics and gynecology, 187 3
-
M. Tuppurainen, M. Komulainen, Heikki Kröger, R. Honkanen, Jukka Jurvelin, E. Puntila, Anna‐Mari Heikkinen, Esko Alhava, Seppo Saarikoski (1998)
Does Vitamin D Strengthen the Increase in Femoral Neck BMD in Osteoporotic Women Treated with Estrogen?Osteoporosis International, 8
-
R. Marcus, Mayme Wong, H. Heath, J. Stock (2002)
Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.Endocrine reviews, 23 1
-
R. Lindsay, D. Hart, C. Forrest, C. Baird (1980)
PREVENTION OF SPINAL OSTEOPOROSIS IN OOPHORECTOMISED WOMENThe Lancet, 316
-
J. Rossouw, G. Anderson, Ross Prentice, Andrea LaCroix, C. Kooperberg, M. Stefanick, R. Jackson, Shirley Beresford, Barbara Howard, Karen Johnson, J. Kotchen, Judith Ockene (2002)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.JAMA, 288 3
-
D. Marshall, O. Johnell, H. Wedel (1996)
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.BMJ, 312 7041
-
S. Cummings, S. Eckert, K. Krueger, D. Grady, T. Powles, J. Cauley, L. Norton, T. Nickelsen, N. Bjarnason, M. Morrow, M. Lippman, D. Black, J. Glusman, Alberto Costa, V. Jordan (2000)
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized TrialObstetrical & Gynecological Survey, 55
-
P. Delmas (1998)
The role of markers of bone turnover in the assessment of fracture risk in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 8 Suppl 1
-
A. Wood, B. Riggs, L. Melton (1992)
The prevention and treatment of osteoporosis.The New England journal of medicine, 327 9
-
M. McClung, P. Geusens, P. Miller, H. Zippel, W. Bensen, C. Roux, S. Adami, I. Fogelman, T. Diamond, R. Eastell, P. Meunier, R. Wasnich, M. Greenwald, Jean Kaufman, C. Chesnut, J. Reginster (2001)
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.The New England journal of medicine, 344 5
-
J. Kanis, O. Johnell, A. Odén, A. Dawson, C. Laet, B. Jönsson (2001)
Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic ThresholdsOsteoporosis International, 12
-
MD Lufkin, MD Wahner, PhD O'Fallon, MD Hodgson, Mbbs Kotowicz, Mph Lane, MD Judd, MD Caplan, MD Riggs (1992)
Treatment of Postmenopausal Osteoporosis with Transdermal EstrogenAnnals of Internal Medicine, 117
-
(1991)
Consensus development conference: prophylaxis and treatment of osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1 2
-
(1998)
Reminder : severe oesophageal reactions with alendronate sodium ( Fosamax ) -
I. Reid, Jacques Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, A. Widmer, J. Devogelaer, J. Kaufman, P. Jaeger, J. Body, M. Brandi, J. Broell, R. Micco, A. Genazzani, D. Felsenberg, J. Happ, M. Hooper, J. Ittner, G. Leb, H. Mallmin, T. Murray, S. Ortolani, A. Rubinacci, M. Saaf, G. Samsioe, L. Verbruggen, P. Meunier (2002)
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.The New England journal of medicine, 346 9
-
F. Lanza, R. Hunt, A. Thomson, J. Provenza, M. Blank (2000)
Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.Gastroenterology, 119 3
-
J. Kanis, E. McCloskey (1996)
Evaluation of the risk of hip fracture.Bone, 18 3 Suppl
-
E. Jenny-Avital (2002)
Bisphosphonates and osteoporosis.The New England journal of medicine, 346 26
-
E. Siris, P. Miller, E. Barrett-Connor, K. Faulkner, L. Wehren, T. Abbott, M. Berger, A. Santora, Louis Sherwood (2001)
Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.JAMA, 286 22
-
S. Bonar, M. Tinetti, M. Speechley, L. Cooney (1990)
Factors Associated with Short‐ Versus Long‐Term Skilled Nursing FacilityJournal of the American Geriatrics Society, 38
-
R. Wasnich, P. Miller (2000)
Antifracture efficacy of antiresorptive agents are related to changes in bone density.The Journal of clinical endocrinology and metabolism, 85 1
-
R. Bouillon, P. Burckhardt, C. Christiansen, HA Fleisch, T. Fujita, C. Gennari, TJ Marin, G. Mazzuoli, L. Melton, J. Ringe, B. Riis, Wallace Peck, G. Samsioe, L. Shulman (2005)
Consensus development conference: Prophylaxis and treatment of osteoporosisOsteoporosis International, 1
-
D. Torgerson, S. Bell-Syer (2001)
Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.JAMA, 285 22
-
Bruce Ettinger, D. Black, B. Mitlak, R. Knickerbocker, Thomas Nickelsen, H. Genant, Claus Christiansen, P. Delmas, J. Zanchetta, J. Stakkestad, Kathryn Krueger, F. Cohen, Stephen Eckert, K. Ensrud, L. Avioli, Paul Lips, S. Cummings (1999)
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.JAMA, 282 7
-
L. Tankó, D. Felsenberg, E. Czerwiński, A. Burdeska, I. Jonkanski, C. Hughes, C. Christiansen (2003)
Oral weekly ibandronate prevents bone loss in postmenopausal womenJournal of Internal Medicine, 254
-
R. Neer, C. Arnaud, J. Zanchetta, R. Prince, G. Gaich, J. Reginster, A. Hodsman, E. Eriksen, S. Ish-shalom, H. Genant, O. Wang, B. Mitlak (2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.The New England journal of medicine, 344 19
-
D. Kiel, D. Felson, Jennifer Anderson, P. Wilson, M. Moskowitz (1987)
Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.The New England journal of medicine, 317 19
-
(1996)
Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.JAMA, 276 17
-
(2002)
clinical practice guidelines for the diagnosis and management of osteoporosis in Canada -
F. Lanza, H. Schwartz, B. Sahba, H. Malaty, T. Musliner, Robert Reyes, H. Quan, D. Graham (2000)
An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosaeAmerican Journal of Gastroenterology, 95
-
G. Guyatt, A. Cranney, L. Griffith, S. Walter, N. Krolicki, M. Favus, C. Rosen (2002)
Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures.Endocrinology and metabolism clinics of North America, 31 3
-
R. Schimmer, F. Bauss (2003)
Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.Clinical therapeutics, 25 1
-
J. Kanis (2002)
Diagnosis of osteoporosis and assessment of fracture riskThe Lancet, 359
-
(2001)
Assessment of fracture risk from bone mineral density and bone markers -
J. Stakkestad, L. Benevolenskaya, J. Stepan, A. Skag, A. Nordby, E. Oefjord, A. Burdeska, I. Jonkanski, P. Mahoney (2003)
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal womenAnnals of the Rheumatic Diseases, 62
-
R. Russell, P. Croucher, M. Rogers (1999)
Bisphosphonates: Pharmacology, Mechanisms of Action and Clinical UsesOsteoporosis International, 9
-
L. Melton, S. Khosla, E. Atkinson, W. O'Fallon, B. Riggs (1997)
Relationship of Bone Turnover to Bone Density and FracturesJournal of Bone and Mineral Research, 12
-
S. Hough (1998)
25th European Symposium on Calcified Tissues entitled 'Defining Typologies in Osteoporosis', Harrogate, April 25, 1997 : Fast and slow bone losers: Relevance to the management of osteoporosis -
R. Mühlbauer, F. Bauss, R. Schenk, M. Janner, E. Bosies, K. Strein, H. Fleisch (1991)
BM 21.0955, a potent new bisphosphonate to inhibit bone resorptionJournal of Bone and Mineral Research, 6
-
L. Davis (1998)
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age.Journal of nurse-midwifery, 43 5
-
D. Greenblatt (2005)
Treatment of Postmenopausal OsteoporosisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 25
-
P. Ebeling, A. Roberts, M. d’Emden, G. Nicholson, C. Crusan, D. Wenderoth, D. Ethgen, M. Hooper (1999)
Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trialClimacteric, 8
-
M. ansen, Kirsten vergaard, Bente JTRs, C. Christiansen (1991)
Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study.British Medical Journal, 303
-
D. Torgerson, S. Bell-Syer (2001)
Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trialsBMC Musculoskeletal Disorders, 2
-
A. Paganini-Hill, R. Ross, V. Gerkins, B. Henderson, M. Arthur, T. Mack (1981)
Menopausal estrogen therapy and hip fractures.Annals of internal medicine, 95 1
-
R. Goodman (2001)
The effect of risedronate on the risk of hip fracture in elderly women.The New England journal of medicine, 344 22
-
C. Cooper, R. Emkey, R. Mcdonald, G. Hawker, G. Bianchi, K. Wilson, R. Schimmer (2003)
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.The Journal of clinical endocrinology and metabolism, 88 10
-
M. Hochberg, S. Greenspan, R. Wasnich, P. Miller, D. Thompson, P. Ross (2002)
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.The Journal of clinical endocrinology and metabolism, 87 4
-
L. Mortensen, P. Charles, P. Bekker, J. Digennaro, C. Johnston (1998)
Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.The Journal of clinical endocrinology and metabolism, 83 2
-
P. Ryan, I. Fogelman (1994)
Clinical experience with etidronate in osteoporosisClinical Rheumatology, 13
-
D. Gold, K. Lyles, K. Shipp, M. Drezner (2001)
Chapter 61 – Osteoporosis and its Nonskeletal Consquences: Their Impact on Treatment Decisions -
S. Cummings, L. Melton (2002)
Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 359
-
T. Schnitzer, H. Bone, G. Crepaldi, S. Adami, M. McClung, D. Kiel, D. Felsenberg, R. Recker, R. Tonino, C. Roux, A. Pinchera, A. Foldes, S. Greenspan, M. Levine, R. Emkey, A. Santora, A. Kaur, D. Thompson, J. Yates, J. Orloff, Alendronate Group (2000)
Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosisAging Clinical and Experimental Research, 12
-
J. Reginster, R. Deroisy, M. Dougados, I. Jupsin, J. Colette, C. Roux (2002)
Prevention of Early Postmenopausal Bone Loss by Strontium Ranelate: The Randomized, Two-Year, Double-Masked, Dose-Ranging, Placebo-Controlled PREVOS TrialOsteoporosis International, 13
-
B. Cryer, D. Bauer (2002)
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?Mayo Clinic proceedings, 77 10
-
D. Hosking, C. Chilvers, C. Christiansen, Pernille Ravn, R. Wasnich, P. Ross, M. McClung, A. Balske, D. Thompson, M. Daley, A. Yates (1998)
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.The New England journal of medicine, 338 8
-
S. Cummings, M. Nevitt, W. Browner, K. Stone, K. Fox, K. Ensrud, J. Cauley, D. Black, T. Vogt (1995)
Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.The New England journal of medicine, 332 12
-
A. Cranney, P. Tugwell, N. Zytaruk, V. Robinson, B. Weaver, J. Adachi, G. Wells, B. Shea, G. Guyatt (2002)
IV. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal OsteoporosisEndocrine Reviews, 23
-
A. Cranney, P. Tugwell, N. Zytaruk, V. Robinson, B. Weaver, J. Adachi, G. Wells, B. Shea, G. Guyatt (2002)
Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis.Endocrine reviews, 23 4
-
P. Maxim, B. Ettinger, G. Spitalny (2005)
Fracture protection provided by long-term estrogen treatmentOsteoporosis International, 5
-
T. Schnitzer, H. Bone, G. Crepaldi, S. Adami, M. McClung, D. Kiel, D. Felsenberg, R. Recker, R. Tonino, C. Roux, A. Pinchera, A. Foldes, S. Greenspan, M. Levine, R. Emkey, A. Nd, A. Kaur, D. Thompson, J. Yates, J. Orloff (2000)
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group., 12
-
D. Gatti, S. Adami (1999)
New Bisphosphonates in the Treatment of Bone DiseasesDrugs & Aging, 15
-
P. Garnero, E. Hausherr, M. Chapuy, C. Marcelli, H. Grandjean, C. Muller, C. Cormier, G. Bréart, P. Meunier, P. Delmas (1996)
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective studyJournal of Bone and Mineral Research, 11
-
S. Cummings, D. Black, D. Thompson, W. Applegate, E. Barrett-Connor, T. Musliner, L. Palermo, R. Prineas, S. Rubin, J. Scott, T. Vogt, R. Wallace, A. Yates, A. LaCroix (1998)
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.JAMA, 280 24
-
Steven Cummings, Stephen Eckert, Kathryn Krueger, Deborah Grady, T. Powles, J. Cauley, Larry Norton, Thomas Nickelsen, Nina Bjarnason, Monica Morrow, Marc Lippman, D. Black, J. Glusman, Alberto Costa, V. Jordan (1999)
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.JAMA, 281 23
-
(2002)
National Osteoporosis Foundation. Physician's Guide -
Joseph Lane, Martin Nydick (1999)
Osteoporosis: current modes of prevention and treatment.The Journal of the American Academy of Orthopaedic Surgeons, 7 1
-
P. Miller, N. Watts, A. Licata, S. Harris, H. Genant, R. Wasnich, P. Ross, R. Jackson, Mohammed Hoseyni, S. Schoenfeld, D. Valent, C. Chesnut (1997)
Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.The American journal of medicine, 103 6
-
Jensen Js, J. Bagger (1982)
Long-term social prognosis after hip fractures.Acta orthopaedica Scandinavica, 53 1
-
M. Luckey, N. Gilchrist, H. Bone, M. Davie, T. Villiers, Mei Wu, A. Daifotis, A. Santora, J. Orloff (2003)
Therapeutic Equivalence of Alendronate 35 Milligrams Once Weekly and 5 Milligrams Daily in the Prevention of Postmenopausal OsteoporosisObstetrics & Gynecology, 101
-
P. Garnero, E. Sornay‐Rendu, B. Claustrat, P. Delmas (2000)
Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY StudyJournal of Bone and Mineral Research, 15
-
T. Storm, G. Thamsborg, T. Steiniche, H. Genant, O. Sørensen (1990)
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.The New England journal of medicine, 322 18
-
P. Delmas, J. Beaudreuil (1997)
Biochemical markers of bone turnover in osteoporosis.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 3 4
-
J. Reginster, M. Lecart, R. Deroisy, Christian Lousberg (2004)
Strontium ranelate: a new paradigm in the treatment of osteoporosisExpert Opinion on Investigational Drugs, 13
-
P. Ross, B. Kress, R. Parson, R. Wasnich, K. Armour, I. Mizrahi (2000)
Serum Bone Alkaline Phosphatase and Calcaneus Bone Density Predict Fractures: A Prospective StudyOsteoporosis International, 11
-
A. Klibanski, L. Adams-Campbell, T. Bassford, S. Blair, S. Boden, K. Dickersin, D. Gifford, L. Glasse, S. Goldring, K. Hruska, Susan Johnson, L. McCauley, W. Russell (2001)
Osteoporosis prevention, diagnosis, and therapy.JAMA, 285 6
-
O. Johnell (1997)
The socioeconomic burden of fractures: today and in the 21st century.The American journal of medicine, 103 2A
-
J. Compston (2000)
Pharmacological interventions for post-menopausal osteoporosis: an evidence-based approach.Rheumatology, 39 12
-
S. Adami, V. Bruni, D. Bianchini, A. Becorpi, P. Lombardi, C. Campagnoli, Andrea Ferrari, T. Marchesoni, R. Balena (2000)
Prevention of early postmenopausal bone loss with cyclical etidronateJournal of Endocrinological Investigation, 23
-
M. Horwitz, A. Stewart, S. Greenspan (2000)
Sequential parathyroid hormone/alendronate therapy for osteoporosis--robbing Peter to pay Paul?The Journal of clinical endocrinology and metabolism, 85 6
- Publisher
- Wiley
- Copyright
- Copyright © 2004 Wiley Subscription Services, Inc., A Wiley Company
- ISSN
- 0954-6820
- eISSN
- 1365-2796
- DOI
- 10.1111/j.1365-2796.2004.01292.x
- pmid
- 15147525
- Publisher site
- See Article on Publisher Site
Abstract
Abstract. Postmenopausal osteoporosis (PMO) is a common disease that will become more prevalent in the future, with costly implications for public health. Prevention of the disease and its consequences, namely fractures, is therefore, important for both the individual and society. This review discusses: the goals of PMO prevention; the identification of women at risk, including the use of bone mineral density and bone turnover markers; the relevance in the prevention setting of various current guidelines for PMO management; recent data on therapeutic options for the treatment and prevention of PMO, in particular bisphosphonates, hormone replacement therapy and several other new pharmacological agents. It concludes that it is crucial for PMO prevention to start before disease onset and that, in the light of recent evidence, the existing guidelines need updating if they are to continue to be relevant.
Journal
Journal of Internal Medicine – Wiley
Published: Jun 1, 2004